FDA AdComm Will Review Vertex’s Off-Target Effects Data for Sickle Cell Gene Therapy

Whether Vertex Pharmaceuticals’ off-target safety analysis of its investigational sickle cell gene therapy exagamglogene autotemcel (exa-cel) is sufficient or not is the issue before an FDA advisory committee on Tuesday…

Continue ReadingFDA AdComm Will Review Vertex’s Off-Target Effects Data for Sickle Cell Gene Therapy

New Database Describes 141 Investigatory Alzheimer’s Drugs, 187 Global Clinical Trials

A new publicly searchable database contains detailed information on all 141 Alzheimer’s disease (AD)-targeting drugs involved in 187 active clinical trials in the U.S. and around the world. Source: Drug…

Continue ReadingNew Database Describes 141 Investigatory Alzheimer’s Drugs, 187 Global Clinical Trials